Canada Markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.0400+0.1800 (+4.66%)
At close: 04:00PM EDT
4.1600 +0.12 (+2.97%)
After hours: 04:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.8600
Bid3.8500 x 1800
Ask4.1600 x 1300
Day's Range3.9300 - 4.0700
52 Week Range3.7900 - 22.2200
Avg. Volume670,123
Market Cap265.375M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Codexis Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as induceme

  • GlobeNewswire

    Codexis to Participate in Cowen 43rd Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo

  • GlobeNewswire

    Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

    Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a busine